Comparative Pharmacology
Head-to-head clinical analysis: DORYX versus MINOLIRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORYX versus MINOLIRA.
DORYX vs MINOLIRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
Sodium-glucose co-transporter-2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
100 mg orally every 12 hours on day 1, then 100 mg orally every 24 hours. For severe infections: 100 mg orally every 12 hours.
60 mg subcutaneously once daily
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in healthy adults; prolonged to 21-36 hours in renal impairment; clinically relevant for once-daily dosing and monitoring for accumulation.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (40-60% as unchanged drug via glomerular filtration), biliary/fecal (20-30% as active and inactive metabolites), incomplete excretion leads to enterohepatic recirculation.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 25%; the remainder undergoes hepatic metabolism.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic